Your browser doesn't support javascript.
loading
Torben Fog - A Danish pioneer in a multi-faceted spectrum of multiple sclerosis research.
Sørensen, Per Soelberg; Bramow, Stephan; Magyari, Melinda; Werdelin, Lene; Koch-Henriksen, Nils; Vermersch, Patrick; Sellebjerg, Finn.
Afiliação
  • Sørensen PS; Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark/Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Bramow S; Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark.
  • Magyari M; Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark/The Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark/Department of Clinical Medicine, Faculty o
  • Werdelin L; Independent Researcher.
  • Koch-Henriksen N; Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
  • Vermersch P; Univ. Lille, Inserm U1172 LIlNCog, CHU Lille, FHU Precise, Lille, France.
  • Sellebjerg F; Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, Glostrup, Denmark/Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Mult Scler ; 30(6): 623-629, 2024 May.
Article em En | MEDLINE | ID: mdl-38523325
ABSTRACT
Torben Fog was committed to multiple sclerosis (MS) research for more than four decades, starting before the defence of his thesis in 1948 and lasting until his death in 1987. His research was multi-facetted, making him one of the great pioneers in the study of essential parts of the pathology, immunology and treatment of MS. He has contributed with meticulous studies of the MS plaques, documenting the perivenous distribution of plaques in the spinal cord. He constructed a scoring system for the disability in MS and used a computer programme to calculate a total neurological deficit. Together with his co-workers, Fog in 1972 was the first to report the association between MS and the human leukocyte antigen system. Fog can be considered as the father of immunomodulatory therapy in MS, treating MS patients with the first transfer factor, and as early as 1980, he was the first to treat MS with intramuscular natural interferon.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Múltipla Limite: Humans País como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article